{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI could not be estimated due to less number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI could not be estimated due to less number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"95% CI could not be estimated due to less number of participants with events.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"8.3"},{"comment":"95% CI could not be estimated due to less number of participants with events.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"9.2"},{"comment":"95% CI could not be estimated due to less number of participants with events.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"12.0"},{"groupId":"OG010","lowerLimit":"1.9","upperLimit":"21.3","value":"3.1"},{"comment":"Upper limit of 95% CI could not be estimated due to less number of participants with events.","groupId":"OG012","lowerLimit":"1.8","upperLimit":"NA","value":"1.9"},{"comment":"Upper limit of 95% CI could not be estimated due to less number of participants with events.","groupId":"OG013","lowerLimit":"1.0","upperLimit":"NA","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"8"}],"units":"Participants"}],"description":"DoR was defined, in participants who achieved a response as time from the first date of response to the first date of recurrent or progression disease. Participants without recurrent or progression disease were censored on date of the last adequate disease assessment, date of initiation of anticancer treatment or death of death, whichever was the earliest.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ABCL who received study drug in Part 2. Response included complete remission and partial remission. Lugano Classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) used for assessment.","id":"OG000","title":"Part 2: Aggressive B-cell Lymphoma (ABCL)"},{"description":"Participants with AML who received study drug in Part 2. Response included morphologic leukemia-free state, morphologic complete remission, morphologic complete remission with incomplete blood count recovery, partial remission. International Working Group for trials in AML (Cheson et al., 2003) was used for assessment.","id":"OG001","title":"Part 2: Acute Myeloid Leukemia (AML)"},{"description":"Participants with CLL who received study drug in Part 2. Response included complete response or complete remission, complete response or complete remission with incomplete marrow recovery, partial response. International Workshop on CLL update of the NCI 1996 Guidelines (Hallek et al., 2008) was used for assessment.","id":"OG002","title":"Part 2: Chronic Lymphocytic Leukemia (CLL)"},{"description":"Participants with HL who received study drug in Part 2. Response included complete remission and partial remission. Lugano Classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) used for assessment.","id":"OG003","title":"Part 2: Hodgkin Lymphoma (HL)"},{"description":"Participants with IBCL who received study drug in Part 2. Response included complete remission and partial remission. Lugano Classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) used for assessment.","id":"OG004","title":"Part 2: Indolent B-cell Lymphoma (IBCL)"},{"description":"Participants with MDS who received study drug in Part 2. Response included complete remission, partial remission, marrow response. International Consortium Proposal of Uniform Response Criteria for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) in Adults (Savona et al., 2015) was used for assessment.","id":"OG005","title":"Part 2: Myelodysplastic Syndrome (MDS)"},{"description":"Participants with MM who received study drug in Part 2. Response included complete response, stringent complete response, very good partial response, partial response. International Uniform Response Criteria for Multiple Myeloma (Durie et al., 2006) was used for assessment.","id":"OG006","title":"Part 2: Multiple Myeloma (MM)"},{"description":"Participants with MPN who received study drug in Part 2. Response included complete remission, partial remission, marrow response. International Consortium Proposal of Uniform Response Criteria for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) in Adults (Savona et al., 2015) was used for assessment.","id":"OG007","title":"Part 2: Myeloproliferative Neoplasms (MPN)"},{"description":"Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL. If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG008","title":"Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination"},{"description":"Participants with PTCL who received study drug in Part 3. Response included complete remission and partial remission. Lugano Classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) used for assessment.","id":"OG009","title":"Part 3: Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG010","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination"},{"description":"Participants with SCLC who received study drug in part 2. Response included irComplete Response, irPartial Response. Immune-Related Response Criteria: irRECIST (Bohnsack et al., 2014) was used for assessment.","id":"OG011","title":"Part 2: Small Cell Lung Cancer (SCLC)"},{"description":"Participants with CTCL who received study drug in Parts 2 and 3. Response included complete response, partial response. Clinical endpoints and response criteria (Olsen et al., 2011) were used in CTCL (mycosis fungoides and Sezary syndrome).","id":"OG012","title":"Parts 2 and 3: Cutaneous T-cell Lymphoma (CTCL)"},{"description":"Participants with TCL who received study drug in Parts 2 and 3. Response included complete remission and partial remission. Response criteria included both Lugano Classification (Cheson 2014/ refinement 2016) and Olsen 2011 used for assessment.","id":"OG013","title":"Parts 2 and 3: T-cell Lymphoma (TCL)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Parts 2 and 3: Duration of Response (DoR)- Disease Indication and Nivolumab/Rituximab Combinations","type":"SECONDARY","unitOfMeasure":"Months"}